Figure 3.
Marked regression in brain parenchymal metastases in a 46 year-old, ALK-positive lung cancer patient treated with alectinib. This patient had previously received both crizotinib and ceritinib, relapsing in the central nervous system after each agent. Axial, T1 post-gadolinium magnetic resonance images A) prior to alectinib and B) on alectinib.